Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients

NCT03146247 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped recruitment was not started

Conditions

Moderate to Severe Plaque Psoriasis

Interventions

DRUG: Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet

Sponsor

Diamant Thaci